Curaleaf Sends Letter to Aurora Shareholders

Curaleaf urged Aurora Cannabis shareholders to tender into its hostile offer of 0.3463 Curaleaf shares plus US$0.75 cash per Aurora share, valuing the proposal at US$4.00 per share and a 45% premium to Aurora's August 10 unaffected 30-day VWAP. Curaleaf projects a combined cannabis platform spanning 17 countries with more than US$1.5B in LTM revenue, nearly US$350M in adjusted EBITDA, and at least US$40M in annual cost synergies. The tender deadline is December 1, 2026; Curaleaf argues Aurora's standalone outlook is deteriorating, citing 14% revenue and 78% adjusted-EBITDA declines over the four quarters through June 30.

Analysis

The relevant signal is not the promotional premium but the bidder's need to take its case directly to target holders: this raises the probability of a prolonged hostile process, a revised consideration mix, or a failed tender rather than a clean near-term close. ACB should trade toward the live value of 0.3463 CURA shares plus cash, but the spread must retain a meaningful discount through the December 1 deadline for regulatory, minimum-tender, and shareholder-resistance risk. Because most consideration is CURA stock, ACB's apparent upside is materially exposed to CURA downside; this is not a conventional cash-merger arbitrage.

For CURA, the market should focus on whether the acquisition is accretive after integration costs and financing dilution, not the stated synergy run-rate. The strategic value is likely in Aurora's non-U.S. medical distribution footprint and incremental regulatory optionality; however, overlapping corporate infrastructure and cultivation assets may require impairment charges before savings emerge. Near term, aggressive public campaigning can cap CURA's multiple by signaling management willingness to issue equity at a potentially cyclical high, while a failed deal would remove that overhang and preserve balance-sheet flexibility.

The contrarian view is that ACB's weak standalone trajectory increases tender pressure, but also makes a rival bid unlikely: strategic cannabis buyers generally value scarce licenses and distribution, not commodity cultivation capacity. The trade therefore hinges on acceptance mechanics rather than a bidding war. Falsifiers are a material ACB defense supported by improved operating guidance, a CURA share-price decline large enough to erode implied consideration, or disclosed tender levels indicating insufficient support as the deadline approaches.

Key Decisions for Investors

• Establish a hedged merger-arb position only if ACB trades at a sufficiently wide discount to the mark-to-market offer value: long 1 ACB share / short 0.3463 CURA shares, with cash consideration treated as downside cushion. Target 8-12% annualized gross spread return through December 1; avoid an unhedged ACB long because the stock component transmits CURA beta.
• Use the September 17 shareholder Q&A as an event-driven information catalyst, not a directional catalyst. Add to the paired position only if management provides verifiable detail on minimum-tender conditions, financing, regulatory timetable, and annual synergy phasing; promotional reiteration alone should not compress the spread.
• Maintain a tactical short CURA versus a cannabis-sector proxy only if the market prices full synergy realization before tender certainty. Cover on evidence of strong tender participation or a revised offer with more cash; the key risk is sector-wide U.S. reform optimism driving CURA higher independent of deal fundamentals.
• Set alerts for offer-value deterioration: reduce or exit the arb if CURA declines enough that implied consideration approaches ACB's unaffected trading range, or if ACB's board releases guidance showing stabilization in revenue, EBITDA, and operating cash flow that credibly supports a standalone valuation above the offer.
• Do not position for a competing bid absent an identifiable bidder and financing evidence. A rival offer would be upside for ACB but is a low-probability catalyst given the target's operating deterioration and the limited universe of scaled strategic buyers.